Cardiac Safety and Efficacy for Early-stage Breast Cancer Patients Treated With Pegylated Liposomal Doxorubicin（PLD)

Inclusion Criteria:

* 1.Subjects had histopathologically confirmed early stage breast cancer with adjuvant chemotherapy treatment evidence;
* 2.Age :18-75years old female;
* 3.High risk of recurrence: axillary lymph node-positive, or axillary lymph node negative with at least one of the following risk factors: triple negative breast cancer, histological grade III, the maximum tumor diameter\> 5cm, Ki 67 ≥ 50%, vascular thrombosis positive;
* 4.ECOG score 0-1;
* 5.Expected survival time ≥ 12 months;
* 6.LVEF ≥ 55%;
* 7.Normal ECG, ST segment depression in patients such as coronary angiography, confirm \<50% stenosis or incidental premature beats are acceptable;
* 8.Bone Marrow Function: ANC：≥1.5×109/L； PLT：≥100×109/L；Hb: ≥90g/L;
* 9.Liver and renal function:Serum creatinine ≤ normal upper limit (ULN) 1.5times; aspartate aminotransferase (AST) and alanine aminotransferase (ALT)≤ULN 2.5times; total bilirubin (TBil) level:≤ ULN 1.5 times, or ≤ ULN 2.5times if Gilbert's syndrome are present;
* 10.Subjects are well-behaved, able to undergo treatment and follow-up, and voluntarily comply with this study and understood the study's research process and signed the informed consent.

Exclusion Criteria:

* 1.New York Heart Association (NYHA) Class II or greater heart failure;
* 2.Severe heart disease or discomfort, including but not limited to: High-risk uncontrolled arrhythmias, atrial tachycardia (heart rate\>100/min at rest), significant ventricular arrhythmias (ventricular arrhythmias) or higher, atrioventricular block (\[Mobitz 2\] or third-degree atrioventricular block); Angina pectoris that needs to be treated with anti-anginal medicine; Valvular heart disease with clinical significance; Electrocardiogram shows transmural myocardial infarction; Uncontrolled high blood pressure(eg: Systolic blood pressure\> 180 mmHg or diastolic blood pressure\> 100 mmHg);
* 3.Prior received neoadjuvant chemotherapy;
* 4.Severe systemic infection or other serious disease;
* 5.Allergies to chemotherapeutic drugs or their excipients or intolerant patients;
* 6.Other malignant tumors have been found in the past 5 years,except for cured cervical carcinoma in situ, non melanoma of the skin;
* 7.Childbearing age patients who are pregnant or lactation and refusing to take effective contraceptive measures during the trial;
* 8.Received any other test drug treatment or participated in other clinical trials at the same time;
* 9.Other conditions considered to be inappropriate to be enrolled by the investigator.